A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-APOC3 in Adult Participants With Dyslipidemia
Latest Information Update: 06 Feb 2025
Price :
$35 *
At a glance
- Drugs ALN APOC3 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 03 Feb 2025 Status changed from not yet recruiting to recruiting.
- 29 Jan 2025 New trial record